ORAGRAFIN CALCIUM
LOE ApproachingNDAORALGRANULEPriority Review
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORAGRAFIN CALCIUM is an oral granule formulation approved in 1962 as a diagnostic agent. The specific mechanism of action and therapeutic indication are not publicly detailed in available data. This legacy product represents a historical pharmaceutical asset with limited contemporary clinical use.
LOE Approaching
Legacy product nearing loss of exclusivity with minimal current market activity and limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORAGRAFIN CALCIUM offers minimal career growth given zero linked job postings and approaching loss of exclusivity. This legacy asset is best suited for professionals focused on portfolio maintenance, regulatory compliance, or manufacturing optimization rather than launch or growth strategies.
Regulatory Affairs SpecialistProduct Manager (Legacy/Maintenance)
Worked on ORAGRAFIN CALCIUM at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.